LEGN Stock Summary and Trading Ideas (Legend Biotech - American Depositary Shares | NASDAQ:LEGN)

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Legend Biotech - American Depositary Shares trades on the NASDAQ stock market under the symbol LEGN.

As of November 13, 2026, LEGN stock price declined to $17.50 with 2,856,510 million shares trading.

LEGN has a beta of 0.70, meaning it tends to be less sensitive to market movements. LEGN has a correlation of 0.01 to the broad based SPY ETF.

LEGN has a market cap of $3.40 billion. This is considered a Mid Cap stock.

Last quarter Legend Biotech - American Depositary Shares reported $360 million in Revenue and $.14 earnings per share. This fell short of revenue expectation by $-409,248 and exceeded earnings estimates by $.13.

In the last 3 years, LEGN traded as high as $70.13 and as low as $16.24.

The top ETF exchange traded funds that LEGN belongs to (by Net Assets): IBB, IEMG, PBE, CANC, PINK.

LEGN has underperformed the market in the last year with a price return of -43.6% while the SPY ETF gained +13.4%. LEGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.7% and -19.1%, respectively, while the SPY returned -2.8% and -0.2%, respectively.

LEGN support price is $17.71 and resistance is $19.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEGN shares will trade within this expected range on the day.